Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without bolus mitomycin-C in patients with carcinoma of unknown primary origin
Source of recordUK Trials
ISRCTNISRCTN63374575
Date ISRCTN assigned19/08/2002
Local reference number(s)RMH E/N 1042
Public titleA randomised study of continuous infusional 5-Fluorouracil (5FU) with or without bolus mitomycin-C in patients with carcinoma of unknown primary origin
Scientific title
AcronymN/A
Disease/condition/study domainUnknown Primary Site
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histological evidence of carcinoma of unknown primary site
2. Patients evaluable for response
3. Must have bi-dimensionally measurable disease as assessed by chest X-ray or Computed Tomography (CT) scan
4. Disease must be outside previously irradiated areas
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated end date30/04/2001
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsTwo arms:
Regimen 1. Protracted Venous Infusion (PVI) 5FU 300 mg/m/day over 24 weeks
Regimen 2. PVI 5FU 300 mg/m/day over 24 weeks Mitomycin-C 7 mg/m (total not to exceed 56 mg). Four courses over 24 weeks
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingRoyal Marsden Hospital
Sponsor nameRoyal Marsden Hospital (UK)
Sponsor detailsDowns Road
Sutton
United Kingdom
SM2 5PT
Sponsor telephone+44 (0)20 8661 3156
Sponsor fax+44 (0)20 8643 9414
Sponsor websitedavid.cunningham@rmh.nhs.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN63374575
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central